Alnylam Pharmaceuticals, Inc. (ALNY)
$
320.42
+1.51 (0.47%)
Key metrics
Financial statements
Free cash flow per share
3.5194
Market cap
42.5 Billion
Price to sales ratio
11.4421
Debt to equity
1.6199
Current ratio
2.7624
Income quality
1.6704
Average inventory
79.1 Million
ROE
0.9035
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alnylam Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of innovative therapeutics based on ribonucleic acid interference. The company reported selling, general, and administrative expenses of $1,210,713,000.00 indicating its operational overhead costs. Additionally, the company incurred an interest expense of $252,627,000.00 reflecting its debt servicing obligations. A net loss of $313,747,000.00 was reported, indicating challenges in its operations. With its stock identified by the symbol 'ALNY' in the market, the weighted average number of diluted shares outstanding is 134,684,000.00 reflecting potential dilution effects. Alnylam's pipeline of investigational RNAi therapeutics addresses a range of conditions, including genetic disorders, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Marketed products such as ONPATTRO (patisiran), GIVLAARI, and OXLUMO highlight its commitment to addressing unmet medical needs. Furthermore, the company is advancing multiple candidates in its pipeline, including givosiran and cemdisiran, enhancing its portfolio with potential therapies for various diseases. Strategic collaborations with prominent partners like Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme bolster its development capabilities. The stock is priced at $453.56 positioning it in the higher-end market. It has an average trading volume of 1,523,527.00 indicating moderate liquidity. With a mid-range market capitalization of $42,495,061,340.00 the company is a steady performer in the competitive landscape. It is a key player in the biopharmaceutical industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth within the field. Alnylam continues to enhance its position through collaborations and partnerships, unlocking new avenues for discovering and delivering RNAi therapeutics. The company's focus on cutting-edge science and strategic alliances marks it as a noteworthy entity in advancing healthcare solutions and addressing complex diseases. As it navigates its challenges, Alnylam remains committed to its vision of transforming the treatment landscape through pioneering biopharmaceutical innovations.
Is Alnylam Pharmaceuticals, Inc. (ALNY) a good investment?
Investing in Alnylam Pharmaceuticals, Inc. (ALNY) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
What is Alnylam Pharmaceuticals, Inc. (ALNY)'s stock forecast?
Analysts predict Alnylam Pharmaceuticals, Inc. stock to fluctuate between $205.87 (low) and $495.55 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alnylam Pharmaceuticals, Inc.'s market capitalization?
As of 2026-03-17, Alnylam Pharmaceuticals, Inc.'s market cap is $42,495,061,340, based on 132,622,999 outstanding shares.
How does Alnylam Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Alnylam Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Alnylam Pharmaceuticals, Inc. (ALNY) stock?
To buy Alnylam Pharmaceuticals, Inc. (ALNY) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALNY. Place an order (Market, Limit, etc.).
What is the best time to invest in Alnylam Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Alnylam Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $3,713,937,000 | EPS: $2.39 | Growth: -209.63%.
Where can I find Alnylam Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.alnylam.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alnylam Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Alnylam Pharmaceuticals, Inc. stock?
All-time high: $495.55 (2025-10-20) | All-time low: $117.58 (2022-05-12).
What are the key trends affecting Alnylam Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
forbes.com
Investing in equities involves accepting volatility as the cost of long-term compounding. In 15 significant systemic shocks during which Alnylam Pharmaceuticals (ALNY) was traded, the stock experienced an average drawdown of -25%.
fool.com
Two analysts weighed in with new evaluations of the biotech. This followed last week's earnings release.
seekingalpha.com
Alnylam Pharmaceuticals has declined nearly 40% from its all-time high, pressured by near-term TTR market dynamics and longer-term profitability concerns. The TTR business will likely remain "noisy" in the first half of 2026, but Amvuttra continues to gain share, and management guidance for 2026 was above expectations. Management alarmed the Street earlier this year with long-term spending guidance that was considerably higher than expected; management continues to prioritize R&D to realize the company's full long-term potential.
zacks.com
Alnylam tops Q4 earnings estimates but misses on sales despite 85% revenue growth, as booming Amvuttra demand fails to lift shares.
fool.com
The biotech released its final set of figures for 2025. It had a mixed quarter, despite the recent success of a popular product.
fool.com
Alnylam will likely report strong sales growth for Amvuttra in its February quarterly update. Management should also provide news about the initiation of two clinical studies.
seekingalpha.com
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
benzinga.com
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) announced a new five-year roadmap, "Alnylam 2030," on Sunday, outlining the company's focus on scaling its operations.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, “Alnylam 2030,” focused on scaling the Company's operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility. Alnylam also today reported preliminary* fourth quarter and full year 2025 global net product.
defenseworld.net
Cerity Partners LLC boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 171.2% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 27,429 shares of the biopharmaceutical company's stock after acquiring an additional 17,316 shares during the quarter. Cerity Partners
See all news
